Expression of p21 and MDM-2 proteins on tumor cells in responding and non-responding patients with Hodgkin's disease

Neoplasma

Volumn 46, Issue 4, 1999, Pages 212-218

  Smolewski, P ^a   Niewiadomska, H ^a   Krykowski, E ^a   Robak, T ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Apoptosis; Hodgkin's disease; Oncoproteins expression; Prognostic factors

Indexed keywords

ONCOPROTEIN; PROTEIN P21;

APOPTOSIS; ARTICLE; DISEASE CONTROL; DNA FLANKING REGION; GENETIC ANALYSIS; HODGKIN DISEASE; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REGRESSION ANALYSIS; SURVIVAL RATE; TUMOR CELL CULTURE;

EID: 0032875651     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. BRINCK, U., STACHURA, J., RUDZKI, Z. et al.: p53 positivity and high proliferative index: Factors of bad prognosis in malignant fibrous histiocytomas. In Vivo, 9, 1995, 475-478.
2. CHEN, W.G., CHEN, Y.Y., KAMEL, O.W., Koo, CH., WEISS, L.M.: p53 mutations in Hodgkin's disease. Lab. Invest., 75, 1996, 519-527.
3. CHILOSI, M., DOGLIONI, C., MENESTRINA, F., MONTAGNA, L., RIGO, A., LESTANI, M., BARBARESCHI, M., SCARPA, A., MARIUZZI, G.M., PIZZOLO, G.: Abnormal expression of the p53 binding protein MDM2 in Hodgkin's disease. Blood, 84, 1994, 4295-4300.
4. CHILOSI, M., DOGLIONI, C., MAGALINI, A., INGHIRAMI, G., KRAMPERA, M., NADALI, G., RAHAL, D., PEDRON, S., BENEDETTI, A., SCARDONI, M., MACRI, E., LESTANI, M., MENESTRINA, F., PIZZOLO, G., SCARPA, A.: p21/WAF1 cyclin kinase inhibitor expression in non Hodgkin's lymphomas: A potential marker of p53 tumor suppressor gene function. Blood, 88, 1996, 4012-4020.
5. DOUSSIS, I.A., PEZZELLA, F., LANE, D.P., GATTER, K.C., MASON, D. Y.: An immunocytochemical study of p53 and bcl-2 protein expression in Hodgkin's disease. Am. J. Clin. Pathol., 99, 1993, 663-667.
6. 1 arrest and apoptosis. Cancer Res., 54, 1994, 1169-1174.
7. ELENITOBA-JOHNSON, K.S., MEDEIROS, L.J., KHORSAND, J., KING, T.C.: p53 expression in Reed Sternberg cells does not correlate with gene mutations in Hodgkin's disease. Am.J .Clin. Pathol., 706, 1996, 728-738.
8. FINNEGAN, M.C., GOEPEL, J.R., ROYDS, J., HANCOCK, B.W., GOYNS, M.H.: Elevated levels of MDM-2 and p53 expression are associated with high grade non Hodgkin's lymphomas. Cancer Lett., 86, 1994, 215-221.
9. GONG, J.Z., ZHOU, H., Hu, Z., SCHULMAN, P., VINCEQUERRA, V., BROOMS, J.D., KODURU, P.: Absence of somatic changes in p21 gene in non Hodgkin's lymphoma and chronic myelogenous leukemia. Hematol.Pathol., 9, 1995, 171-177.
10. HANNA, E., BODROGI, I., INSTITORIS, E., BAK, M.: Correlation between p53 expression and clinical resistance in testicular cancer. Orv. Hetil., 137, 1996, 59-64. (In Hungarian.)
11. HOCKENBERY, D.: The bcl-2 oncogene and apoptosis. Semin.Oncol., 4, 1992, 413-420.
12. IMMAMURA, J., MIYOSHI, I., KOEFFLER, H.P.: p53 in hematologic malignancies. Blood, 84, 1994, 2412-2421.
13. KAWAMATA, N., MILLER, C., LEVY, V, SHINTAKU, I.P., KOEFFLER, H.P., SAID, J.W.: mdm 2 oncogene expression in non Hodgkin's lymphomas. Diagn. Mol. Pathol., 5, 1996, 33-38.
14. KRAMER, M.H., HERMANS, J., PARKER, J., KROL, A.D., KLUINNELEMANS, J.C., HAAK, H.L., VAN GRONINGEN, K., VAN KRIEKEN, J.H., DE JONG, D., KLUIN, P.M.: Clinical significance of bcl2 and p53 protein expression in diffuse large B cell lymphoma: A population based study. J.Clin.Oncol., 14, 1996, 2131-2138.
15. LEONCINI, L., SPINA, D., CLOSE, P., MINACCI, C., MEGHA, T., DE LUCA, F., TOSI, P., PILERI, S., KRAFT, R., LAISSUE, J.A., COTTIER, H.: Mitotic activity and nuclear DNA damage of large cells in Hodgkin's disease: Comparison with the expression of p53 and bcl-2 proteins and the presence of Epstein-Barr virus.
16. LOUIE, D.C., OFFIT, K., JASLOW, R., PARSA, N.Z., MURTY, V.V., SCHLUGER, A., CHAGANTI, R.S.: p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11.,14)(q13.,q32). Blood, 86, 1995, 2892-2899.
17. MAESTRO, R., GLOGHINI, A., DOGLIONI, C.: Human non Hodgkin's lymphomas overexpress a wild type form of p53 which is a functional transcriptional activator of the cyclindependent kinase inhibitor p21. Blood, 89, 1997, 2523-2528.
18. MAESTRO, R., GLOGHINI, A., DOGLIONI, C., GASPAROTTO, D., VUKOSAVLJEVIC, T., DE-RE, V., LAURINO, L., CARBONE, A., BOIOCCHI, M.: MDM2 overexpression does not account for stabilization of wild type p53 protein in non Hodgkin's lymphomas. Blood, 85, 1995, 3239-3246.
19. MARTINEZ DELGADO, B., ROBLEDO, M., ARRANZ, E., INFANTES, F., ECHEZARRETA, G., MARCOS, B., SANZ, C., RIVAS, C., BENITEZ, J.: Correlation between mutations in p53 gene and protein expression in human lymphomas. Am.J.Hematol., 55, 1997, 1-8.
20. MARTINEZ, J.C., MATEO, M., SANCHEZ-BEATO, M., VILLUENDAS, R., ORRADRE, J.L., ALGARA, P., SANCHEZ-VERDE, L., GARCIAC, P., LOPEZ, C., MARTINEZ, P.: MDM2 expression in lymphoid cells and reactive and neoplastic lymphoid tissue. Comparative study with p53 expression. J. Pathol., 177, 1995, 27-34.
21. MORENTE, M., PIRIS, A.P., ABRAIRA, V, ACEVEDO, A., AGUILERA, B., BELLAS, C., FRAGA, M., GARCIA-DEL-MORAL, R., GOMEZ-MARCOS, F., MEARGUEZ, J., OLIVA, H., SANCHEZ-BEATO, M., MONTALBAN, C.: Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression. High Ki67 proliferation index, and absence of Epstein-Barr virus - latent membrane protein 1 expression. Blood, 90, 1997, 2429-2436.
22. NARESH, K.N., O'CONNOR, G.T., SOMAN, C.S., JOHNSON, J., ADVANI, S.H., MAGRATH, I.T., BHATIA, K.G.: A study of p53 protein, proliferating cell nuclear antigen, and p21 in Hodgkin's disease at presentation and relapse. Human Pathol., 28, 1997, 549-555.
23. OSADA, M., ISHIOKA, C., MURAKAWA, Y., ICHINOHASAMA, R., KANAMARU, R., IKAWA, S.: p53 mutation does not determine prognosis in non Hodgkin's lymphoma. Gan. To. Kagaku. Ryoho., 24, 1997, 471-475.
24. OTTO, A., WOLFGANG, D.: Upregulation of mdm-2 expression in meth A tumor cells tolerating wild-type p53. Oncogene, 8, 1993, 2591-2603.
25. PASMAN, P.C., TIEBOSCH, A., ERDKAMP, F.L., VRINTS, L.W., BREED, W.P., SCHOUTEN, H.C.: 53 as a marker of the malignant cell in Hodgkin's disease. Ann.Oncol., Suppl. 1, 5, 1995, 89-91.
26. PIRIS, M.A., PEZZELLA, F, MARTINEZ MONTERO, J.C., ORRADRE, J.L., VILLUENDAS, R., SANCHEZ-BEATO, M., CUENA, R., CRUZ, M.A., MARTINEZ, B., GARRIDO, M.C., GATTER, K., AIELLO, A., DELIA, D., GIARDINI, R., RILKE, F.: p53 and bcl-2 expression in high grade B cell lymphomas: Correlation with survival time. Br.J.Cancer, 69, 1994, 337-341.
27. PIRIS, M.A., VILLUENDAS, R., MARTINEZ, J.C., SANCHEZ-BEATO, M., ORRADRE, J.L., MATEO, M.S., MARTINEZ, P.: p53 expression in non Hodgkin's lymphomas: A marker of p53 inactivation? Leuk.Lymph., 17, 1995, 35-42.
28. QUESNEL, B., PREUDHOMME, C., OSCIER, D., LEPELLEY, P., COLLYN-D'HOOGHE, M., FACON, T., ZANDECKI, M., PENAUX, P.: Overexpression of the MDM2 gene is found in some cases of haematological malignancies. Br. J. Haematol., 88, 1994, 415-418.
29. SANCHEZ-BEATO, M., PIRIS, M.A., MARTINEZ-MONTERO, J.C., GARCIA, J.F., VILLUENDAS, R., GARCIA, F.J., ORRADRE, J.L., MARTINEZ, P.: MDM2 and p21WAF1/CIP1, wild type p53 induced proteins, are regularly expressed by Sternberg Reed cells in Hodgkin's disease. J. Pathol., 180, 1996, 58-64.
30. SMOLEWSKI, P., NIEWIADOMSKA, H., BROŃSKI, J.Z., ROBAK, T., KRYKOWSKI, E.: Expression of proliferating cell nuclear antigen (PCNA) and p53, bcl-2 or C-erb B-2 proteins on Reed-Sternberg cells: Prognostic significance in Hodgkin's disease. Neoplasma, 45, 1998, 140-147.
31. TZARDI, M., KOUVIDOU, C., PANAYIOTIDES, I., KOUTSOUBI, K., STEFANAKI, K., GIANNIKAKI, E., DARIVIANAKI, K., ZOIS, M., ELIOPOULOS, G., KAKOLYRIS, S., DELIDES, G., RONTOGIANNI, D., KANAVAROS, P.: Expression of p53 and mdm 2 proteins in Hodgkin's disease. Absence of correlation with the presence of Epstein-Barr virus. Anticancer Res., 16, 1996, 2813-2819.
32. VAUX, L.: Toward an understanding of the molecular mechanisms of physiological cell death. Proc. Natl. Acad. Sci., 90, 1993, 786-791.
33. VILLUENDAS, R., PEZZELLA, F., GATTER, K., ALGARA, P., SANCHEZ-BEATO, M., MARTINEZ, P., MARTINEZ, J.C,. MUNOZ, K., GARCIA, P., SANCHEZ, L., KOCIALKOWSKY, S., CAMPO, E., ORRADRE, J.L., PIRIS, M.A.: p21WAF1/CIP1 and MDM2 expression in non Hodgkin's lymphoma and their relationship to p53 status: A p53+, MDM2, p21 immunophenotype associated with missense p53 mutations. J.Pathol., 181, 1997, 51-61.
34. WATANABE, T., HOTTA, T, ICHIKAWA, A., KINOSHITA, T., NAGAI, H., UCHIDA, T., MURATE, T., SAITO, H.: The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low grade lymphoma of B cell origin. Blood, 84, 1994, 3158-3165.
35. WILSON, W.H., TERUYA-FELDSTEIN, J., FEST, T., HARRIS, C., STEINBERG, S.M., JAFFE, E.S., RAFFELD, M.: Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non Hodgkin's lymphomas. Blood, 89, 1997, 601-609.
36. WYLLIE, A.H.: Apoptosis and the regulation of cell numbers in normal and neoplastic tissues. Cancer Metast.Rev., 11, 1992, 95-
37. XERRI, L., BOUABDALLAH, R., CAMERLO, J., HASSOUN, J.: Expression of the p53 gene in Hodgkin's disease: Dissociation between immunohistochemistry and clinicopathological data. Hum. Pathol., 25, 1994, 449-454.